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ABSTRACT

ANTIBODY DEPENDENT ENHANCEMENT
OF VISCERAL LEISHMANIASIS
by
Alan K. McNolty
December 2018
Leishmaniasis is a parasitic disease caused by protozoans of the genus
Leishmania. This vector-born disease, transmitted by biting phlebotomine sandflies,
typically manifests in one of three ways. The cutaneous form of the disease is
characterized by localized lesions of the skin and is by far the most common
manifestation. The visceral form of the disease is caused by parasitic infiltration of
internal organs, particularly the spleen, liver, and bone marrow. The mucocutaneous
form is caused by parasitic infection of the mucosa in the nose or mouth. While
cutaneous leishmaniasis (CL) is often self-healing, visceral leishmaniasis (VL) is fatal if
left untreated. Mucocutaneous leishmaniasis (MCL) can lead to severe facial
disfigurement if left untreated but is not particularly deadly. The geographic range of the
disease is broad, encompassing areas in Asia, Africa, South America, and the warmer
regions of Europe and North America. It is estimated nearly 3 million people are infected
by any manifestation of the disease each year and roughly a billion people live in
endemic areas. Treatments for the disease are available, though demanding treatment
regimens and high costs can be prohibitive for many. No vaccine is currently available,
but previous exposure generally confers immunity against future exposures to the same
iii

species of Leishmania. The antiquated practice of leishmanization takes advantage of
this. The process involves the administration of exudate from active CL lesions to an
open wound on an individual to be immunized. It is believed this practice is still used in
some areas.
Given the fact parasites known to cause CL have considerable geographic overlap
with those that cause VL it is possible for people in endemic areas to have exposures to
both in their lifetime. This calls into question the disease outcomes for individuals that
experience heterologous secondary exposure after recovering from earlier infection.
Studies have addressed this question by using L. major as a primary infection followed
by L. infantum challenge in the murine model. Results are contentious, with reports of
heterologous protection against L. infantum and others reporting disease exacerbation.
Observations of increased disease severity hint at the possibility of antibody dependent
enhancement of infection (ADE).
Herein we explore the possibility of extrinsic ADE as a result of heterologous
exposure to L. major and L. infantum in vitro. ELISA was done to verify cross reactivity
of L. major antiserum to antigen derived from both L. major and L. infantum. Results
indicate substantial cross reactivity to the two antigens. This was followed with
phagocytosis assays to measure parasite uptake by macrophages in vitro. J774
macrophages were combined with either L. major or L. infantum in the presence of L.
major antiserum, naïve serum, or no serum. Parasite uptake was measured at several
time points using flow cytometry. In the presence of L. major antiserum we observed
significantly higher rates of L. major uptake but no effect on L. infantum uptake. Our
results would suggest increased disease severity observed by others in vivo is not a result
iv

of extrinsic ADE. We hypothesize biased memory T cell responses, possibly as a result
of intrinsic ADE caused by Fcγ signaling, could account for disease exacerbation in the
animal model.
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CHAPTER I
INTRODUCTION
Leishmaniasis is a disease caused by protozoan parasites belonging to the genus
Leishmania. The genus is comprised of 53 species, around 20 of which are known to
infect humans (Akhoundi et al. 2016). The parasite is transmitted by biting phlebotomine
sandflies and can be found in the warmer regions of South America, Africa, Europe, and
Asia. There are two ways in which Leishmania infection will usually manifest; either as
cutaneous leishmaniasis (CL) or visceral leishmaniasis (VL). CL is the most common
form of infection and is characterized by open, weeping sores. These sores, though grisly
in appearance, are often reported to be painless by patients (Borghi et al. 2017).
Generally, this type of infection will self-heal in weeks or months (Nadim et al. 1997;
Markle & Makhoul 2004). VL causes a more diffuse infection that attacks the internal
organs, particularly the spleen and liver. VL is characterized by fever, abdominal
swelling, and a dark ashen coloration of the skin. This form of leishmaniasis is usually
fatal when left untreated (Alvar et al. 2012).
There are also rarer forms of the disease such as mucocutaneous leishmaniasis
(MCL) and post-kala azar dermal leishmaniasis (PKDL). MCL is characterized by
parasitization of the mucosal membranes of the nose and mouth. It is most often caused
by parasites within the L. braziliensis species complex and transmission occurs almost
exclusively in South America (reviewed by Torres-Guerrero et al. 2017). PKDL is
characterized by a resurgence of disease months or years after recovery from VL. PKDL
presents as small papules that can appear all over the body that can sometimes be
resolved without treatment (Zijlstra et al. 2003). The manner in which the disease
1

presents is dependent on the species of Leishmania causing the infection as well as host
immunophenotype.
The global impact of leishmaniasis is far-reaching. It is estimated that there are
up to 3 million new cases each year, leading to as much as 50,000 fatalities annually
(Lozano et al. 2012; Mathers, Ezzati & Lopez 2007). The World Health Organization
has identified leishmaniasis as a neglected tropical disease in need of further study.
Leishmaniasis is also ranked second to malaria as the deadliest parasitic disease in terms
of death toll (Mathers, Ezzati & Lopez 2007). The primary risk factor for people living in
endemic areas is poverty and the associated living conditions. To be more specific, risk
of exposure is higher for people who spend many hours outdoors, people who are not
adequately clothed, and people lacking adequate shelter. Increased rates of transmission
have also been linked to urbanization, population mobility, environmental change, animal
husbandry, and destabilization caused by warfare (Oryan & Akbari 2016).
Effective treatment options for this disease are available, though steep cost and
demanding treatment regimens can be prohibitive for those without access to proper
medical care. There are also prevention strategies for both individuals and communities.
Community prevention generally comes in the form of municipal programs aimed at
preventing malaria. Fortuitously, many of the techniques used to control malariacarrying mosquitoes are also effective against the sandflies that carry Leishmania
(Reyburn et al. 2000; Claborn 2010; Zofou et al. 2014). Municipal prevention techniques
include vector control, environmental management, disease surveillance, and control of
animal hosts (Reyburn et al. 2000; Claborn 2010). On the individual level, it is advised
that one should use bed nets, dress adequately and use insect repellents if possible
2

(Claborn 2010). Another, more antiquated method of prevention is leishmanization. This
is the practice of collecting exudate from active lesions of those afflicted with CL and
administering them to a skin abrasion of another individual to intentionally infect and
confer some degree of immunity. This method, though prone to side effects, has been
shown to be effective at preventing future cases of CL (Nadim, Javadian & Mohebali
1997; Peters et al. 2009). One issue that has not been addressed is the fact that strains of
Leishmania known to cause CL and those that cause VL tend to co-occur geographically
(Pigott et al 2014). This calls into question the potential outcomes for individuals that
have undergone leishmanization or had natural exposure to CL, only to have later
exposure to VL.
The present study is certainly not the first to explore the potential for cross
protection between Leishmania species. Two studies done by a team of Brazilian
researchers investigated potential outcomes associated with heterologous exposures to
American leishmaniases. They began by producing soluble Leishmania antigen (SLA)
extracted from L. amazonensis, a causative agent of CL. The SLA was used to immunize
mice which were later challenged with L. braziliensis, a causative agent of MCL. The
immunized mice showed increased susceptibility to L. braziliensis (Silva et al. 2011).
Silva and colleagues noted that the disease exacerbation was associated with high titers of
L. amazonensis antibody. In a subsequent experiment these researchers replicated their
earlier findings and identified a particular antigenic protein present in L. amazonensis
SLA that is responsible for the deleterious antibody production (Silva et al. 2015).
The topic of potential cross protection through heterologous exposures has also
been examined in the context of Old World leishmaniases. There have been a number
3

studies that examine how previous exposure to L. donovani or its constituent antigens can
lend protective effects against L. major (Mitchell & Handman 1987; Rachamim & Jaffe
1993; Gicheru, Olobo & Anjili 1997). These authors all noted heterologous protection
against L. major. Indeed, L. donovani appears to be a popular subject of interest for its
potential to invoke immunity to other species. Other studies have endeavored to find
potential cross protection conferred by L. donovani against L. mexicana, L. amazonensis,
L. tropica, and L. chagasi (Dey et al. 2014; Nico et al. 2014; Manson-Bahr 1961;
Aguilar-Be et al. 2005). The rationale behind all these studies is solid, though it could be
argued they are not necessarily reflective of real-world conditions. Parasites known to
cause CL are more geographically widespread than their VL inducing relatives and CL is
considerably more prevalent on a global scale (Pigott et al. 2014; Alvar et al. 2012).
Additionally, the old practice of leishmanization is likely still used in certain localities
and is looked to by some as a viable method of disease prevention (Khamesipour et al.
2005). As recently as the late 1980’s Iran implemented mass leishmanization that saw
nearly 2 million people undergo inoculation (Nadim et al. 1997). This is all to say that
individuals in endemic areas are more likely to have been exposed to/recovered from CL
than VL. With this in mind, CL would seem to be a logical starting point when
considering potential outcomes of heterologous exposures.
A few inquiries have been structured this way, opting to use exposure to L. major
as a foundation to study immunological cross reactivity toward VL, particularly L.
infantum. Though the matter has been investigated by multiple studies, results are
discordant. One publication examining the effects of heterologous immunization used L.
major as an inoculum to confer future protection against L. chagasi (infantum) in the
4

BALB/c model. The authors found no such effect and observed similar parasite burden
between naïve animals and those that had been primed with L. major (Streit et al. 2001).
Another study went down this same path of inquiry, using an initial inoculation of L.
major followed by challenge with L. infantum in the BALB/c model. In this instance, the
authors reported an increase in tissue parasite burden as well as detrimental cytokines
among the L. major-primed group when compared to the naïve control group, indicating
disease exacerbation. (Nation, Dondji & Stryker 2012). Another study using passive
serum transfer yielded supportive results. Three groups of BALB/c mice were treated
with either naïve serum, L. major antiserum, or live L. major. These groups were then
challenged with L. infantum and parasitemia was measured. Results indicated
substantially higher parasite burdens in recovered individuals and even higher burdens in
individuals treated with L. major antiserum (Anderson, Dondji & Stryker 2014). The
most recent study on the matter followed the same line of inquiry as the others,
inoculation with L. major followed by challenge with L. infantum. However, the
C57BL/6 model was used. In this instance the authors noted lower parasite burden in L.
major recovered animals compared to the naïve control group, suggesting a protective
effect (Romano et al. 2015). These contradictory findings speak to complexity of the
mechanisms at play and call for further investigation.
The findings of Nation et al. (2012) and those of Anderson et al. (2014) seem to
hint at the possibility of antibody dependent enhancement (ADE); a potentiality that is
rarely considered in the context of leishmaniasis. ADE is a phenomenon wherein an
individual that has had previous exposure to a particular pathogen experiences a more
severe infection when later exposed to the same or a closely related pathogen. The
5

mechanism behind this is dependent on the presence of antibody generated during the
first infection. Over time, antibody concentration may fall below levels necessary for
neutralization. Alternatively the antibody may be incapable of neutralizing a closely
related pathogen. If the pathogen in question targets the cells of immunity the presence
of antibody can be counterproductive. When a second infection occurs the nonneutralizing antibody will opsonize the pathogen either directly or by inducing
compliment deposition. These opsonized pathogens serve as an attractant for phagocytes
which can become infected upon arrival. This process exacerbates the infection by
allowing the pathogen more opportunities to take hold while depriving the host of
valuable leukocytes. ADE has been implicated in the pathogenesis of other diseases
known to attack antigen presenting cells (APCs) such as Dengue virus, yellow fever, Zika
virus, and Chikungunya virus (Katzelnick et al. 2017; Gould & Buckley 1989; Bardina et
al. 2017; Lum et al. 2018). Given Leishmania’s proclivity for APCs, particularly
macrophages, it is entirely possible that the presence of non-neutralizing antibodies from
a previous exposure could augment rates of infection. It has been demonstrated that the
presence of antibody can induce production of detrimental cytokines and exacerbate
leishmaniasis (Kima et al. 2000; Anderson & Mosser 2002; Miles et al. 2005; Buxbaum
2008; Deak et al. 2010).
With this in mind, we set out to further investigate the possibility of ADE of L.
infantum infection after previous exposure to L. major. First, L. major antiserum cross
reactivity to L. major and L. infantum antigen was demonstrated using ELISA. This was
followed up with an in vitro experiment to directly measure rates of parasite uptake by
host cells. Macrophages of the J774 line were combined with L. infantum in the presence
6

of L. major antiserum, control serum, or no serum and prevalence of unbound
Leishmania was measured at several time points using flow cytometry. Prevalence of
infected macrophages were measured at 24 hours. L. major antiserum did not induce
increased L. infantum uptake compared to the controls. Our results would seem to
exclude the possibility extrinsic ADE leading to increased parasite entry of host cells.
However, intrinsic ADE mediated by Fcγ signaling and associated IL-10 production may
still be the cause of increased disease severity in immunized individuals as observed by
others.
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CHAPTER II
LITERATURE REVIEW
Discovery and Early Work on Leishmania
Major William B. Leishman first observed Leishmania in
1900 while serving with the British Army near Kolkata, India
(Leishman 1903 A). Leishman was investigating an enigmatic
disease thought to be an unusual variety of malaria. He referred to
the malady as “Dum-dum fever”, so named for a locality near
Kolkata that produced numerous cases of the unknown disease.
While examining the spleen of a recently deceased Irish soldier,
Leishman noted large numbers of ovoid bodies within the

Figure 1: William
B. Leishman
1865-1926.
Credit: Wellcome
Collection, London

splenocytes. He commented on two chromatin containing masses, one considerably
larger than the other, within these ovate bodies. Later, while working with a mouse
experimentally infected with African trypanosomiasis, Leishman observed these same
characteristic chromatin masses. These masses were of course the nuclei and kinetoplasts
of the parasites. Based on these observations, Major Leishman correctly postulated that
the causative agent of “Dum-dum fever” was a trypanosome.
Working concurrently but independently, Captain
Charles Donovan made a similar observation to that of
Leishman. He too had been examining the spleens of deceased
individuals believed to have died of malaria. He noted the
same ovate bodies described by Leishman, but believed them
8

Figure 2: Charles
Donovan 1863-1951.
Credit: Wellcome
Collection, London

to be an artifact of degraded splenocytes. After reading Leishman’s description of the
same bodies he was able to see the similarity with his own observations. To confirm,
Donovan collected a biopsy from the spleen of a young boy suffering from kala-azar and
the same ovate bodies were present (Ross 1903A).
The suggestion that these Leishman-Donovan bodies, as they came to be known,
were trypanosomes was initially disputed. Donovan himself doubted they were
trypanomastids as did Major Ronald Ross, a correspondent to both Leishman and
Donovan. Ross consulted the French physician Alphonse Laveran, a well-regarded
expert in microscopic parasites at the time. Laveran suggested that
the Leishman-Donovan bodies were a new species, belonging to
the order Piroplasmida (Ross 1903B). The primary reason for
resistance to Leishman’s idea that the observed bodies were
trypanosomes came from the fact that they lacked flagella; a
Figure 3: Ronald
Ross 1857-1932.
Credit: Wellcome
Collection, London

characteristic believed to be defining of trypanosomes at the time. In
a correspondence to Ross, Leishman defended his assertion, stating:

“. . . it is perhaps possible that the life history of some trypanosomata may include a
stage of encystment, such a condition known to occur in other members of flagellata
[sic].” (Leishman 1903B, pg. 1377). Leishman’s description of “encystment” proved to
be prophetic as it seems to allude to the existence of what is now known as the
amastigote. Ultimately, Leishman’s arguments proved to be compelling. In further
correspondences Ross conceded that the Leishman-Donovan bodies could in fact be
trypanosomes of a new genus and consequently, proposed the name Leishmania donovani
for the newly discovered organism (Ross 1903, 1904). Leishmania’s trypanomastid
9

classification was further solidified in 1905 when Drs. Chatterjee and Rogers were able to
culture Leishmania collected from a patient’s spleen. After being cultured for three days
in a solution of sodium citrate, Chatterjee commented on the presence of “elongated
flagellate bodies”, making him the first person to view promastigotes (Chatterjee 1905).
It was very soon after this that the nature of cutaneous leishmaniasis was
elucidated. The disease then known as “Delhi boil” or “tropical ulcer” had been studied
for some time. It is likely that the parasite was first observed in 1884 by Dr. David D.
Cunningham. His descriptions of stained and sectioned tissue may indicate the presence
of amastigote-like bodies. However, he incorrectly classified the organisms he saw as
belonging to “Monadinae”, a now defunct subclass of slime molds (Cunningham 1885).
The American physician John H. Wright made similar observations to those of
Cunningham but came to a different conclusion. He declared these small, intracellular
bodies to be a new protozoan species which he referred to as “Helcosoma tropicum”
(Wright 1903).
Despite these earlier misclassifications, German scientist Dr. Max Luhe was able
to synthesize the recent findings surrounding the new parasite and formulated a fairly
complete understanding of the organism for the time. Luhe commented on Leishman’s
descriptions of the two chromatin masses within each cell or “cores” as Luhe referred to
them. Luhe agreed that the two differently-sized cores are reminiscent of other known
trypanosomes. He supported this assertion with Chatterjee and Roger’s descriptions of
the cultured, flagellated form of the parasite. Luhe was also aware of Wright’s new
species, “Helcosoma tropicum” and stated that it is nearly identical in appearance to
organisms described by Leishman. He concluded that the two organisms must be closely
10

related and proposed renaming Wright’s parasite Leishmania tropica. He also
highlighted key differences between Leishmania and known trypanosomes. He noted the
lack of an undulating membrane in the organism’s motile form as well as the close
proximity of the smaller core to the flagellum. In addition to this, Luhe stated that
Leishmania inhabits marcrophages of the spleen but are never found in “red blood”; an
apparent contrast between other trypanosomes commonly observed in peripheral
circulation. Based on these dissimilarities, he concluded that Leishmania must be a
group related to, but distinct from other trypanosomes (Luhe 1906).
Not long after this, Leishmania was described in the Americas. The discovery of
New World cutaneous leishmaniasis was credited to Italian
physician Antonio Carini working with Brazilian researcher,
Ulysses de Freitas Paranhos as well as dermatologist Adolpho
Lindenberg who worked independently of the former two. The
discovery was made during the construction of the Northwest
Brazil Railroad when large numbers of workers developed

Figure 4: Adolpho
Lindenberg 1872-1944.

lesions of the skin and mucous membranes (Jogas 2017).

Credit: Wellcome Collection,
London

Leishmanial parasites were identified in biopsies and exudates of these so-called “Bauru
ulcers” (Lindenburg 1909, Carini & Paranhos 1909). Initially, the causative agent was
thought to be L. tropica as seen in the Old World, due to morphologically identical
parasites and a similar cutaneous manifestation (Carini & Paranhos 1909).
There was, however, dispute over the notion that the infections observed in South
America were indeed the same as those in the Old World. In fact, the first objection
came from Carini who himself had initially stated the parasites were indistinguishable
11

from L. tropica two years previously. He later commented that mucocutaneous
manifestations of the disease were not uncommon in Brazil, a stark contrast to
descriptions of Old World CL (Carini 1911).
This notion of dissimilarity between old and New World Leishmania was
strengthened by a paper published by the Peruvian doctor, Edmundo Escomel. In it he
gave the first full description of MCL or what he called espundia. His paper pointed out
that mucocutaneous manifestations can appear months or years after a cutaneous episode.
He also described a much longer duration for American MCL and CL; sometimes lasting
years or never resolving (Escomel 1911). Escomel later sent tissue samples to French
scientists Alphonse Laveran and Louis Nattan-Larrier who confirmed that they did
contain leishmanial parasites (Laveran & Nattan-Larrier 1912). While they agreed that
the parasites did seem to bare subtle differences to L. tropica, they were still hesitant to
classify the American parasites as a new species. Italian physician, Affonso Splendore,
who is also credited with elucidating the nature of MCL, contended that the causative
agent of espundia must be a unique species and proposed the name “L. americana”
(Splendore 1911).

There was considerable back and forth on the issue for
some time. Laveran and Nattan-Larrier suggested the causative
agent of espundia may be unique to L. tropica because of subtle
differences in morphology and behavior in culture (Laveran &
Nattan-Larrier 1912). Brazilian scientist, Gaspar Vianna
observed what he described as a filament within the ovate bodies
12

Figure 5: Gaspar
Vianna 1885-1914.
Credit: Biblioteca
Virtual Carlos Chagas

of American Leishmania. He concluded that since the filament had yet to be described in
Old World specimens, his American specimens must be a new species (Vianna 1911).
Laveran and Nattan-Larrier responded to this with hesitation, but ultimately agreed it was
fair to differentiate the Brazilian parasite based on clinical manifestation rather than
morphology, in the same manner L. tropica and L. donovani had previously been
classified. This position was met with some resistance from British physician, Patrick
Manson. Manson agreed that while differing geographic distributions and clinical
manifestations could point to multiple species, he thought it more likely that clinical
manifestation was dependent on the parasite’s passage through differing intermediate
hosts before being deposited in its human host (Manson 1914). This position may seem
somewhat unusual and unsupported by evidence, but even so it was given a measure of
credibility thanks to Manson’s prominent position in the field of tropical disease. The
issue was anticlimactically settled in 1914 when Vianna published a paper referring to the
causative agent of espundia as L. braziliensis; a classification that has endured.

13

Phylogeny & Prehistoric Origins

Figure 6: Classification of Leishmania. Begins with order Trypanosomatidae followed by
genus Leishmania, subgenera Euleishmania and Paraleishmania as proposed by Cupolillo et
al. 2000*, subegenera Leishmania and Viannia, and a non-exhaustive list of species relevant
to human health. Blue box indicates Old World species, yellow box indicates New World
species. Shapes next to species names indicate disease type: o= CL, ⦁= VL, ∎= MCL.
(Shaw 1994; reviewed by Akhoundi et al. 2016)
** L. chagasi is generally considered synonymous with L. infantum.

Leishmania's origins extend deep into prehistory and remain the subject of
discourse. The earliest known specimen of an ancestor to Leishmania was discovered in
an ancient piece of Burmese amber dating to the early Cretaceous, ~110-100 MYA, at the
14

most recent (Poinar & Poinar 2003). The parasite was found
in the digestive tract of the now extinct sandfly species
Palaeomyia burmitis. The fact that promastigotes,
amastigotes, and paramastigotes were observed in the amber
sample would suggest that the lineage already had an
established dimorphic life history. The ancient parasite was
classified as Paleoleishmania proterus. DNA analysis has
not been carried out due to concerns over destroying the
specimen, for this reason it is not immediately clear how P.

Figure 7: Early Cretaceous
Myanmar amber sandfly,
Palaeomyia burmitis.
Credit: George Poinar Jr. (2014)

proterus is related to contemporary Leishmania.
The earliest fossil evidence of phlebotomine sandflies is congruent with the
aforementioned amber-encased Leishmania specimens. The oldest specimens that can be
confidently classified as phlebotomine were found in Baltic and Lebanese ambers dating
to the early Cretaceous, 110-150 MYA (Hennnig 1972;
Azar et al. 1999). The appearance of phlebotomine
ancestors in the fossil record also corresponds nicely to the
proliferation of early mammals roughly 170 MYA (Rowe
Figure 8: Procyclic
promastigotes
of Paleolishmania
proterus developing in the
midgut of sandfly shown in
figure 7.

2017). Additionally, these timeframes are supported by
molecular evidence. Operator metric analysis of 9S and
12S mitochondrial rRNA can provide rough estimates as to

Credit: George Poinar Jr. (2014)

the timeframe over which sequence changes occur. Once
such analysis including L. tarentolae, T. cruzi, T. brucei, and Leptomonas sp. Indicated
that Leishmania likely diverged from Trypanosoma 110 ± 30 MYA (Lake et al. 1988).
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Work done using nuclear rRNA yielded supportive results. Analysis of nuclear rRNA
using L. major, L. donovani, Endotrypanum sp., B. caudatus, T. cruzi, T. brucei,
Phytomonas sp., E. gracilis, and Leptomonas sp. was done to elucidate relationships
between the genera and fossil evidence was used to calibrate divergence timeframes
(Fernandes, Nelson & Beverley 1993). These results indicate Leishmania and
Endotrypanum diverged at least 90 MYA. Collectively, fossil and molecular evidence
strongly point to the emergence of Leishmania sometime in the mid to late Cretaceous.
However, the geographical origin of the parasite and how it spread across the globe is
still a matter of debate.
The earliest hypothesis as to the geographic origin of the parasite suggests that it
evolved in the Palearctic region (Lysenko 1971; Kerr 2000; Kerr, Merkelz & Mackinnon
2000). Current understanding of the fossil record indicates that murine rodents and
ancestors of phelobotomine sandflies also evolved in the Palearctic, supporting the notion
that Leishmania may have emerged there also (Norwalk 1999; reviewed by Lewis 1982).
It has been hypothesized that burrows of these early rodents were sufficiently warm and
humid to be conducive of sandfly development (Kerr 2000). This would have allowed
ample opportunity for a parasite to potentially jump from one species to the other, given
their close proximity to one another. The Palearctic hypothesis goes on to suggest that
the parasites and their hosts eventually crossed the Bering land bridge into the Nearctic
56-34 MYA (Hopkins 1959). After the land bridge submerged, the American sandflies
and their corresponding parasites became isolated in the Nearctic some 34-23 MYA (Kerr
2000). The ancestors of American sandflies and Leishmania we then able to make their
way into the Neotropics when the Isthmus of Panama formed ~3 MYA, joining the North
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and South American continents. Critics of the Palearctic origin hypothesis have
suggested that the greater diversity among American Leishmania would point to the
genus having originated in the New World (Croan, Morrison & Ellis 1997; Lainson &
Shaw 1987). This is not necessarily the case though, as it has been shown that the rate of
speciation in a given setting is not constant and is influenced by other factors such as
geographic isolation, behavioral isolation, and changes in climate or geology (Sepkoski
1998). The Palearctic hypothesis does become somewhat confounding when trying to
explain why New World species belonging to the subgenus Leishmania are more closely
related to their Old World counterparts rather than the exclusively American subgenus
Viannia.
The Palearctic hypothesis as championed by Lysenko and Kerr was later rebutted
by the Neotropical hypothesis as put forth by Noyes. According to this hypothesis,
Leishmania diverged from Endotrypanum 53-65 MYA (Noyes 1998; Noyes et. al 2000).
Endotrypanum is only known to parasitize sloths of the New World and is transmitted by
sandflies of the genus Lutzomyia (Christensen & Herrer 1976). Given their ancient
relationship, overlapping biogeography, and shared vector it could be inferred that
Leishmania and Endotrypanum have a shared origin in the Neotropic. The hypothesis
goes on to state that proto-Leishmanial species were likely monoxenous parasites of early
sandflies. As these sandflies developed hematophagy, their parasites may have become
accustomed to mammalian blood. For this reason, it is suggested that sloths were the first
mammalian host for Leishmania as they have lower body temperatures, serve as hosts for
both Leishmania and Endotrypanum, and were prevalent during the mid-Cenozoic
(Noyes 1998). The parasite is said to have then adapted to porcupines where the lineage
17

again split. This gave rise to L. hertigi, known to parasitize only New World porcupines,
and the progenitor of modern Leishmania (Noyes 1998). From here the infected
porcupines could have introduced the parasite to the Nearctic, after which it was carried
into the Palearctic by an unknown mammal. The Neotropical hypothesis has been
criticized by some who point to indications that porcupines were not present in the
Nearctic until after the formation of the Isthmus of Panama, 3 MYA (Nowak 1999,
Marshall et al. 1982). This is half a million years after the Bering land bridge would have
become inundated and glaciated, meaning Leishmania and its associated hosts would
have been unable to carry it into the Palearctic. There is also debate as whether or not
Lutzomyia was present in the Neotropic at the specified time. The earliest known
Lutzomyia specimen, which also was found to carrying Paleoleishmania, came from a
piece of Dominican amber dated to 20-30 MYA (Poinar 2008). As previously
mentioned, the earliest Old World specimens are in excess of 100 million years old
(Poinar 2004). Thus, the fossil record would also seem to refute the Neotropical
hypothesis.
The supercontinent hypothesis is the most recent hypothesis as to the geographic
origin of Leishmania and would seem to carry the strongest support at this time.
According to this hypothesis, the progenitors of subgenera Leishmania and Viannia were
originally separated during the break-up of Gondwana 140-120 MYA (Momen &
Cupolillo 2000). When the rift that became the Atlantic Ocean formed, the lineage that
would become Viannia and Paraleishmania/Endotrypanum was isolated on the South
American continent while the predecessors to the subgenera Leishmania and
Sauroleishmania were left on the African continent. This hypothesis also provides a
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plausible explanation for the presence of species representative of subgenus Leishmania
in the New World. Momen and Cupolillo speculate that, given the similarities between
L. major and the L. mexicana complex, there must have been a second introduction of
Leishmania into the New World (Lainson & Shaw 1987; Momen & Cupolillo 2000).
Proponents of the supercontinent theory propose that an L. major-like parasite was
carried across the Bering land bridge during the Eocene, some 56-34 MYA (Hopkins
1959). This second introduction can account for the anomalous presence of the L.
mexicana complex.
In a discussion regarding geographic origins of Leishmania it is worth mentioning
the peculiarity of L. chagasi. A fair number of studies have shown that L. chagasi and L.
infantum are practically indistinguishable as evidenced by comparison of morphology, in
vitro behavior, isoenzyme analysis, monoclonal antibody binding assays, and genetic
analysis (Braga et al. 1986; Kreutzer, Souraty & Semko 1987; Grimaldi, David &
McMahon-Pratt 1987; Beverley, Ismach & McMahon-Pratt 1987; Kuhls et al. 2017).
The most well-supported and seemingly logical explanation for the uncanny similarity
would be that Old World L. infantum was introduced to the New World either by
European colonists, African slaves, or imported animals (Momen, Grimaldi & Deane
1987; Mauricio, Stothard & Miles 2000).

Immunology & Course of Infection
Given Leishmania's deep evolutionary history as an endoparasite, it is
unsurprising that it has developed an impressive array of armaments and defenses used to
subvert and evade host immune responses. Though, the converse is also true. Since
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Leishmania's mammalian hosts coevolved alongside it, they too have a number of
methods to contend with the parasite. Consequently, the battle between the two
organisms is often a close match and the outcome of infection, particularly in humans,
can be unpredictable. The infection process is governed by a complex exchange between
parasite and host and is unique to the Leishmania strain and the host's immunological
phenotype. The present review will explore potential interactions between host and
parasite throughout the progression of infection.
Manipulation of sandfly vector
Of course the process of infection begins when an infected sandfly stops to take a
blood meal from a vertebrate host. In preparation for reaching infective maturity, the
parasites move to the anterior midgut of their sandfly host. At this point they are
incapable of passing beyond the stomodeal valve, which serves to prevent the sandfly
from regurgitating its gut contents. The parasites then secrete lytic enzymes capable of
degrading chitin, of which the stomodeal valve is composed (Schlein, Jacobson & Messer
1992). The parasites will also secrete promastigote secretory gel (PSG), a thick
proteophosphoglycan-containing substance, into the foregut and mouth parts of the
sandfly (Rogers & Bates 2007). The PSG plug inhibits feeding and induces
regurgitation. These modifications to the host physiology increase the tenacity with
which infected sandflies bite and causes them to regurgitate Leishmania-laden PSG into
the dermis of the vertebrate host, increasing the probability of establishing infection.
More often than not, the course of infection ends here. In humans, the vast
majority of Leishmania exposures fail to establish symptomatic infection. This can be
evidenced by observations that, of the roughly one billion people living in endemic areas,
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the estimated global incidence of VL is 202,000-389,000 and the estimated incidence of
CL is 690,000-1.2 million (Alvar et al. 2012). For both diseases combined, this works
out to a prevalence of .09-.15% for populations in endemic areas. The low rate of
successful infections can likely be attributed to effective host immune response and the
relatively small inocula incurred via natural transmission- often less than 1000
promastigotes per bite (Kimblin et al. 2008).
Complement
Upon entry into a mammalian host, Leishmania must first avoid destruction by
complement. It has been generally accepted that amastigotes and log phase
promastigotes are considerably more vulnerable to complement than stationary phase,
metacyclic promastigotes (Puentes et al. 1988; Noronha et al. 1998; Dominguez et al.
2002). However, more recent studies indicate that complement takes a heavy toll, even
on metacyclic promastigotes. In one study it was shown that, upon exposure to human
serum, a given promastigote will be fully complement-bound within one minute and 8595% will be killed within 2.5 minutes (Dominguez et al. 2002). This general trend was
true for L. major, L. amozonensis, L. donovani, and L. infantum. These findings are
congruent with a similar study on L. infantum which also showed ~90% of promastigotes
were killed within minutes upon exposure to human serum (Moreno et al. 2007).
However, promastigotes of the viscerlizing species would seem to be more resistant to
destruction by complement than the cutaneous species, a trait that likely enhances their
ability to establish systemic infection (Hoover et al. 1984; Dominguez et al. 2002).
It has been generally accepted that the alternative pathway is the most responsive
to Leishmania and the most likely to be invoked upon exposure (Mosser & Edelson 1984;
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Puentes et al. 1988; Wozencraft & Blackwell 1987). This has been demonstrated by
observing parasite lysis using C2 and C4 deficient sera as a means of inhibiting the
classical and mannose-binding lectin (MBL) pathways to isolate the effects of the
alternative pathway (Mosser & Edelson 1984; Dominguez et al. 2002). There is also
compelling evidence that the classical pathway plays a significant role in elimination of
Leishmania from blood serum. It has been shown that in vitro exposure to immune
serum destroys ~50% more amastigotes in a given time frame than naïve serum (Hoover
et al. 1985). It was later shown that IgM, even in non-immune serum, is primarily
responsible for enhanced complement activation and destruction of parasites (Navin,
Krug & Pearson 1988). Another study concluded that, in normal human serum, the
alternative and classical pathways operate in tandem but ~85% of parasite-bound C3 was
deposited as a result of activation of the classical pathway by anti-Leishmania antibody in
non-immune serum (Dominguez et al. 2002). Additionally, it has been shown that MBL
will bind Leishmania and induce complement activation in vitro, though it is not clear if
the MBL pathway plays a major role in parasite clearance in vivo (Green et al. 1994;
Ambrosio & Messias-Reason 2005).
If an invading promastigote is to have any hope of establishing infection it must
first overcome the onslaught of host complement. Leishmania carries a number of
defenses for protection against complement, some of which are better understood than
others. These defense mechanisms are located on the cell surface and include
lipophosphoglycan (LPG), the metalloprotease glycoprotein 63 (GP63), and leishmanial
protein kinase-1 (LPK-1). It should be noted that LPG is differentially expressed
throughout the parasite’s life cycle and serves many purposes. Experimentation with
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LPG deficient L. major indicates significant detriment to the parasite’s ability to resist
lysis by complement and survive in the phagolysosome (Spath et al. 2003). Metacyclic
promastigotes have LPG polymers that are twice as long, on average, as those expressed
in amastigotes, possibly enhancing their complement survival (McConville et al. 1992).
Parasites which lack functional genes for GP63 have been shown to be more sensitive to
lysis by complement when compared to their wild-type counterparts (Joshi et al. 1998).
This same study demonstrated that GP63 deficient L. major is not crippled in its ability to
survive in the sandlfy vector, infect host macrophages, or induce symptomatic infection
in BALB/c mice; this would suggest the protein is specialized for complement
subversion. Despite being used to deflect the destructive effects of complement, GP63
avidly binds C3 and catalyzes production of iC3b (Russell 1987; Brittingham et al. 1995).
Using this ingenious maneuver the parasite is able to avoid aggravating a complement
cascade while still benefitting from the opsonizing properties of iC3b to gain entry to
phagocytes using CR3. In addition, it would appear that promastigotes have a fail-safe
mechanism to prevent the full insertion of a membrane attack complex (MAC) by
inducing the spontaneous dissociation of C5b9 (Puentes et al. 1990). It is however still
unclear as to how the parasite is able to buck the MAC. Lastly, LPK-1 is capable of
phosphorylating C3, C5, and C9 effectively rendering them inactive and preventing
invocation of the classical and alternative pathways (Hermoso et al. 1991; Forsberg et al.
1990).
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Neutrophils
The first host cell Leishmania parasites encounter is most often a neutrophil (van
Zandbergen et al. 2004; Carlsen et al. 2013; Salei et al. 2017). Most comprehensive
studies into the interaction between the parasite and neutrophils have only been carried
out in recent years and understanding of the matter is still being refined. To be sure, the
nature of this interaction is complex and would sometimes seem contradictory. For
example, of four studies examining the effect of artificial neutrophil depletion prior to
infection with L. major in the BALB/c model, two showed a protective effect (TacchiniCottier et al. 2000; Ribeiro-Gomes et al. 2004) and two showed a detrimental effect
(Lima et al. 1998; Chen et al. 2005). Clearly these conflicting reports have value and
allude to a much more nuanced mechanism at play.
Neutrophils are drawn to the site of infection immediately and reach their highest
concentration between 12 and 24 hours post infection (Sousa et al. 2014). Both
promastigotes and amastigotes are readily phagocytosed by neutrophils and are able to
avoid destruction in lysosomes (Carlsen et al. 2013; Salei et al. 2017; Mollinedo et al.
2010). The parasite avoids destructive measures by barricading itself in non-lytic
compartments that do not readily fuse with antimicrobial granules (Gueirard et al. 2008;
Mollinedo et al. 2010). It should be pointed out that Leishmania does not always survive
within the neutrophil. Gueirard et al. (2008) describe both “spacious” compartments,
which are fatal, and “tight” compartments which allow survival. Interestingly, the safe
“tight” compartments show markers commonly found on endoplasmic reticula, hinting at
a potential mechanism of phagolysosome avoidance. The ability to dodge the
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phagolysosome has been shown to be LPG dependent, though the exact mechanism has
yet to be elucidated (Gueirard et al. 2008).
Infected neutrophils appear to delay apoptosis as long as days after phagocytosing
Leishmania. During this time they secrete MIP-1β, a macrophage attractant (Aga et al.
2002; van Zandbergen et al. 2004). There is evidence to suggest that Leishmania can use
neutrophils as a “Trojan horse” to gain entry to their ultimate target, the macrophage. An
elegant study by van Zandbergen et al. (2004) demonstrated that L. major taken up by
human neutrophils was able to survive but not replicate or revert to the amastigote form.
It was demonstrated in the same study that these infected neutrophils were phagocytosed
by macrophages in which replicative infection was established in vitro. What truly
occurs in vivo is not yet entirely clear. It would seem that the interplay between parasite,
neutrophil, and macrophage is heavily context dependent with regard to parasite species,
host immunophenotype, and the nature of exposure.

Macrophage Entry
The nature of Leishmania-macrophage interactions has a robust body of literature
behind it. When it comes to entering the macrophage, “silent entry” is imperative for
parasite survival. This is a task easier said than done. The macrophage carries an array
of cell surface receptors designed to detect, phagocytose, and degrade pathogens. For
this reason, Leishmania has developed means to activate said receptors in just the right
manner to allow for entry into the host cell while not provoking formation of a fully
activated phagolysosome.
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Complement receptors
As previously mentioned, the process often begins with the parasite allowing the
deposition of iC3b on its surface. The iC3b serves as a non-provocative opsonin that acts
on complement receptor (CR) 3(Mosser & Edelson 1985; Brittingham et al. 1995). In the
presence of serum, Leishmania has been shown to bind CR1 and CR3 as both metacyclic
and log phage promastigotes (Rosenthal et al. 1996; Ueno et al. 2009). The early and late
phase promastigotes are capable of binding both receptors and gaining entry, however log
phase parasites are drawn deep into the macrophage and degraded while metacyclics
enter but remain near the cell membrane and resist degradation (Ueno et al. 2009). It is
unclear why CR1 is involved as blocking this receptor would not appear to affect parasite
entry. However, blocking CR3 causes a marked decrease in parasite internalization
(Rosenthal et al. 1996; Wilson & Pearson 1988).
Toll-like receptors
Toll-like receptors (TLRs) play a pivotal role not only in macrophage infection,
but also development of an adaptive response (Faria, Reis & Lima 2012). Inquiry into
the role of TLRs with regard to leishmaniasis began by observing the course of infection
in C57BL/6 mice lacking MyD88, the downstream signaling protein of all but one TLR.
The mice showed greatly impaired resistance to the disease compared to wild type
controls, indicating TLRs do have involvement in disease progression (Muraille et al.
2003). Further experimentation indicated that promastigote derived LPG acts as a ligand
for TLR2 (Veer et al. 2003). The same study also showed that activation of TLR2 by
LPG did induce signal transduction via MyD88 leading to phosphorylation of MAPK.
Strangely, activation of TLR2 seemed to initiate opposing processes. Resultant MAPK
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activation induced nuclear translocation of NF-κB and gave rise to pro-inflammatory
TNF-α but also increased expression of SOCS-1 and SOCS-3 (Veer et al. 2003). It is
possible that the opposing pro-inflammatory and anti-inflammatory responses to MAKP
phosphorylation will tilt one way or the other, giving rise to the characteristic Th1 and
Th2 adaptive responses, and ultimately determining disease outcome.
The works described above focused largely on MyD88 signaling which were most
useful in constructing an understanding of TLR involvement in Leishmania infection.
However, this did not provide a complete picture, as TLR3 uses TRIF as a signaling
molecule rather than MyD88 and TLR4 has both MyD88 dependent and independent
pathways (Johnson, Li & Pearlman 2008; Laird et al. 2009). To address this, another
study examined the effect of knocking out TLRs 2 and 3 as well as the downstream
signalers MyD88 and IRAK-1 in IFN-γ-primed macrophages. It was demonstrated that
all four proteins are involved in TNF-α secretion and nitric oxide (NO) production, and
by extension, parasite clearance (Flandin, Chano & Descoteaux 2006). The authors went
on to report that silencing either TLR2 or 3 reduced parasite uptake by macrophages. It
was also reported that host cells lacking TLR3 were considerably more susceptible
parasite induced death than those that carried the receptor (Flandin, Chano & Descoteaux
2006). Paradoxically, these receptors appear to promote recovery, but are also
permissive for initial infection. This would suggest that TLR3 plays a role in parasite
detection and clearance, though it is not clear what component of Leishmania is detected
by the receptor.
Additionally, there is evidence indicating TLR4 is involved in parasite clearing
processes. TLR4 knockout C57BL/6 mice show increased parasitemia and recovery time
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(Kropf et al. 2004). The glycosphigophospholipid antigen of L. donovani appears to act
as a ligand for TLR4 as well as L. mexicana derived proteoglycolipid complex P8
(KIarmakar et al. 2012; Whitaker et al. 2008). Both these molecules seem to elicit a
protective response. Another study demonstrated that neutrophil elastase, an
inflammatory protease, can act as a ligand for TLR4 (Ribeiro-Gomes et al. 2007). This
suggests a possible in vivo mechanism for TLR4 activation via neutrophils. Infection by
the sandfly would attract phagocytes and initiate cytokine production. Amid the morass
of inflammation, neutrophils can shed their inflammatory elastase, activating TLR4 on
macrophages and inducing microbicidal activity (Ribeiro-Gomes et al. 2007).
TLR9 also seems to have involvement in Leishmania infection, though current
research suggests that it contributes to signaling with dendritic cells (DCs) and
development of the adaptive response (Fakher et al. 2009; Weinkopff et al. 2013). The
receptor’s role during the acute phase of infection, if any, has yet to be elucidated.
Other receptors
Experimentation has demonstrated that the mannose-fuccose receptor (MFR)
plays a role in parasite entry. Blocking this receptor reduces parasite uptake by ~40%
compared to the control (Wilson & Pearson 1988). Furthermore, data would indicate that
CR3 and MFR may have a synergistic effect on parasite uptake (Wilson & Pearson
1988). Leishmania has also been shown to engage in apoptotic mimicry. Apoptotic cells
illicit a sedated response from macrophages and thus mimicking this would be a logical
stratagem for the parasite. Indeed, the parasites utilize exposed phosphatidylserine (PS)
residues to masquerade as apoptotic cells to induce their own uptake while minimizing
the possibility of a violent response from the macrophage (Balanco et al. 2001;
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Wanderley et al. 2006). Exposure to PS promotes production of IL-10 and TGF-β, down
regulates TNF-α, IL-1, IL-12, and NO production, all while generally making the
macrophage more permissible to quiet infiltration (Voll et al. 1997; Balanco et al. 2001).
The manner in which PS is used is dependent upon life stage of the parasite.
Promastigotes employ a fascinating tactic by which two subpopulations exist
within a given inoculum: those that carry PS and those that do not. PS+ promastigotes
appear to undergo apoptosis as an altruistic gesture meant to induce a non-inflammatory
response from the macrophage, allowing their PS- siblings to enter and establish
residence in the host cell (Wanderley et al. 2009). There is some debate as to whether
promastigotes actually contain PS or a similar phospholipid such as phosphatidic acid,
phosphatidylethanolamine, phosphatidylglycerol or phosphatidylinositol (Weingärtner et
al. 2012). Never the less, the final outcome is the same.
Amastigotes, on the other hand, coat themselves in PS without the need for any
actual apoptosis (Balanco et al. 2001; Wanderley et al. 2006). Interestingly, the amount
of cell surface PS expressed by parasites seems to be responsive to host immunity.
Amastigotes derived from BALB/c mice carry considerably more PS than those derived
from C57BL/6 (Wanderley et al. 2006). Furthermore, cytokine alteration shows direct
correlation with amount of PS exposure while NO synthesis is inversely correlated with
PS exposure (Wanderley et al. 2006).
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Survival in the Host Cell
Phagosome interference
If Leishmania parasites manage to gain entry into a host marcrophage, they must
still contend with the unforgiving conditions they find there. Survival for the parasite
depends on avoiding or subverting the acidic pH, reactive oxygen species (ROS), and
especially NO found in the phagolysosome (Liew et al. 1990; Carneiro et al. 2016).
Promastigotes specialize in bridging insect-mammalian transmission and host cell entry.
They are poorly equipped to survive long term within a host macrophage are thus obliged
to assume their amastigote form to avoid destruction. To achieve this the parasite must
buy time while contained in the relative safety of phagosome before fusion with the
lysosome occurs. The multipurpose LPG coat of promastigotes is known to dampen
formation of the phagolysosome, possibly by altering the curvature and rigidity of the
phagosomal membrane (Desjardins & Descoteaux 1997; Miao et al. 1995). Promastigote
derived LPG is used to further ensure survival by interfering with the membrane
trafficking protein, synaptotagmin V (Syt V). Syt V recruits proton-ATPase pumps to the
phagosome to drive down internal pH. Thus, by interfering with Syt V, the parasite is
effectively able to prevent acidification of the phagosome (Vinet et al. 2009). These
impediments to phagosome development seek to ensure successful reversion to the
amastigote form.
Defense against reactive oxygen and nitrogen species
One of the primary dangers to Leishmania shortly after cell entry is ROS (Murray
1982). ROS are produced by NADPH oxidase which is assembled from both cytosolic
and membrane proteins (Huang & Kleinberg 1999). Two key proteins, p47phox and
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p67phox, necessarily must translocate to the phagosomal membrane in order to create the
NADPH complex (Leo et al. 1996). It has been shown that L. donovani is capable of
stopping translocation of p47phox and p67phox by preventing their phosphorylation by
protein kinase C (Dey et al. 2005; Lodge, Diallo & Descoteaux 2006). The latter study
indicated that the effect appeared to be dependent on LPG of promastigotes. However,
Dey et al. (2005) witnessed a similar reduction in ROS production when amastigotes
were used, despite LPG expression being altered and significantly down regulated in
amastigotes (Turco & Sacks 1991). This is either evidence of LPG’s potency or possibly
implies a LPG-independent mechanism of NADPH interference.
Even after the parasite has achieved the amastigote form and established
residence in the cell, it must remain diligent to ensure continued survival. Part of this
involves the continued effort to blunt production of ROS and NO. Parasites produce
ROS neutralizing enzymes generally referred to as peroxidoxins. Two peroxidoxins
isolated from L. chagasi, LcPxn1 & 2 have been shown to protect against different types
of ROS (Barr & Gedamu 2003). LcPxn1 in particular also has the ability to neutralize
peroxynitrite, a reactive nitrogen species produced from the combination of superoxide
with NO (Barr & Gedamu 2003; reviewed by Pacher, Beckman & Liaudet 2007). The
parasite also defends against ROS by actively neutralizing it using super oxide dismutase
(Ghosh, Goswami & Adhya 2003). In macrophages NO is enzymatically produced from
arginine but the parasite also requires arginine for ornithine synthesis. For these reasons,
Leishmania actively robs the host cell of available arginine, minimizing the host’s ability
to muster a NO response while satisfying its own need for the amino acid (Acuña et al.
2017).
31

Resource sequestration
Leishmania is known to steal more than just arginine from the host cell. The
parasite requires exogenous sphingolipids in order to transition from promastigote to
amastigote (Zhang et al. 2003). The host sphingolipids are gleaned for this purpose,
remodeled, and incorporated into parasite membrane components (Zhang et al. 2005).
Sphingolipid theft appears to be purely an act of sabotage for L. mexicana which is fully
capable of synthesizing its own. This is in contrast to L. major, for which the pilfered
membrane components are vital (Ali, Harding & Denny 2012).
Iron is the object of a similar skirmish between parasite and host. Iron cations are
used by Leishmania as a cofactor for protective superoxide dismutase and are necessary
for parasite growth (Paramchuk et al. 1997). Ironically, divalent iron ions are also
required by macrophages in order to produce the very ROS which the parasites must
defend against ( reviewed by Bedard & Krause 2007). Leishmania is certainly not the
only pathogen that benefits from iron and consequently macrophages have evolved iron
efflux pumps to deprive their endosomes of divalent iron (Gruenheid et al. 1999). In
macrophages these transporters are natural resistance associated macrophage protein
(Nramp) 1 & 2. Nramp1 exists in lysosomal membranes while Nramp2 is found in most
other endosomes (Gruenheid et al. 1997; Jabado et al. 2002). Leishmania employs its
own iron sequestration mechanisms including heme transporter LHR1, ferrous transporter
LIT1, and ferric to ferrous iron reductase LFR1 (Miguel et al. 2013; Huynh, Sacks &
Andrews 2006; Flannery et al. 2011).
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Intercellular Signaling Interference
With its immediate security ensured, the parasite must now direct its efforts to
evading and sabotaging the adaptive immune response; an endeavor for which
Leishmania is extraordinarily well-equipped. The parasite employs a number of
techniques to avoid drawing the attention of T cell lymphocytes and hinder their
response.
MHC Interference
To prevent invocation of an effective adaptive response a logical first step would
be to silence any attempts by the host cell to communicate distress signals. To that end,
Leishmania has several strategies to interfere with MHC II signaling. It begins by
actively internalizing the MHC II molecules lining the phagosome in which it resides
(Lang et al. 1994; De Souza Leao et al. 1995). The parasite is apparently able to draw the
MHC II deep within its cytoplasm where it is degraded by cysteine proteases. Of course
the parasite can only access MHC lining the parasitophorous vacuole and so further
countermeasures are needed.
Another strategy is to interfere with antigen loading onto MHC II. It is known
that macrophages lose their ability to display Leishmania specific antigen via MHC II as
the parasites transition from promastigotes to amastigotes (Kima et al. 1996; Prina et al.
1996). The impaired antigen presentation is specific to leishmanial antigen but
expression of MHC II and use of costimulatory signals are unaffected (Kima et al. 1996).
Further research would suggest the process of antigen sequestration is mediated by GP63
(Matheoud et al. 2013). This research showed GP63 was able to cleave SNARE proteins
vital to proper phagosome function. The crippled phagosomes were unable to properly
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process and transport antigen for loading onto MHC I. It is not clear if this same process
is used to subvert MHC II.
The host cell is prepared to counter these attacks on MHC signaling. When the
concentration of presentable antigen is very low, antigen presenting cells (APCs) are
known to construct low-solubility lipid rafts rich with MHC II. These rafts are meant to
stimulate T cells more effectively than would be possible with a more diffuse distribution
of MHC (Huby, Dearman & Kimber 1999; Anderson, Hiltbold & Roche 2000).
However, Leishmania anticipates this countermeasure and acts accordingly. Infected
macrophages have been shown to have increased membrane fluidity, resulting in less
cohesive MHC rafts (Chakraborty et al. 2005). Affected cells were shown to be
considerably less capable of stimulating T cells. Another study suggests a possible
mechanism for decreased membrane fluidity. The authors demonstrated LPG is capable
of intercalating into host cell membranes and disrupting lipid rafts (Winberg et al. 2009).
However, this research focused on lipid rafts associated with phagosomal maturation,
thus it is not known if the same process affects MHC rafts.
Alteration of cytokine signaling
The fate of Leishmania within the host ultimately depends on the elicited T cell
response. T cell responses are driven by cytokine signaling and for this reason the
parasite takes active measures to influence a more favorable outcome. It has been known
for some time that the parasite is able to subvert IFN-γ signaling to discourage the Th1
response. The method employed is disruption of JAK/STAT signaling to render infected
cells less responsive to stimulation by IFN-γ (Nandan and Reiner 1995; Blanchette et al.
1999). Others have shown infected macrophages display impaired secretion of IL-12, a
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key Th1 cytokine (Reiner et al. 1994; Weinbeber et al. 1998). The mechanism behind
this is not known with certainty. Weinbeber et al. (1998) noted that IL-12 mRNA
transcription did not appear to be affected by infection. Expression of NO was also
unaffected (Reiner et al. 1994). A more recent study found a link between IL-12
inhibition and CR3 activation but noted that functionality of MAPK and NF-κB signaling
as well as transcription factors ETS and IRF were all unaffected (Ricardo-Cartier et al.
2013). Though the parasite’s mode of IL-12 interference is not fully understood, it could
be linked to preferential induction of IL-10 in infected cells. Two studies done on the
cytokine production of infected cells reported preferential production of IL-10 (Chandra
& Naik 2008; Meddeb-Garnaoui, Zrelli & Dellagi 2009). In both cases IL-10 production
had an inverse correlation with IL-12 secretion. This was attributed to suppression of
TLR2 mediated signaling by inhibition of MAPK P38 phosphorylation accompanied by
increased phosphorylation of ERK1/2 (Chandra & Naik 2008).
Chemokine modulation
There is good evidence to suggest Leishmania is capable of altering the localized
chemokine environment of lesions. A thorough study conducted by Katzman & Fowell
(2008) examined the expression of several chemokines in the dermis of L. major infected
mice compared to mice receiving ovalbumin (OVA) with adjuvant. In the early stages of
infection the authors noted down regulation of most chemokines except CCL7, a potent
M2 macrophage attractant (Xuan et al. 2014). A subsequent experiment was done in
which mice received L. major in one ear and OVA+adjuvant in the other. Later, mice
were challenged with OVA+adjuvant. Elevated levels of IL-4 were exhibited in the
infected ears as was selective recruitment of Th2 cells (Katzman & Fowell 2008). Other
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studies have examined chemokine receptor expression during infection. One inquiry on
the matter demonstrated sustained increases in CCR1, CCR7, and CXC4 (Pinheiro et al.
2006). The purpose of this may be to direct the host cell toward chemokine signatures
indicative of conditions prosperous for the parasite. Alteration of chemokine receptor
density also appears to be species dependent. L. major induces greater upregulation of
CCR2, CCR3, and CCR5 than L. donovani, perhaps owing the localized nature of L.
major infection (Matte & Olivier 2002). Leishmania is also capable of secreting its own
chemotactic agents. It was demonstrated that promastigote culture medium contains a
chemotactic factor that attracts neutrophils (van Zandbergen et al. 2002). The reason for
attracting these neutrophils may be to use them as an intermediate host cell, serving as a
staging point prior to infecting macrophages.
It is also worth mentioning the curious case of macrophage migration inhibitory
factor (MIF). The nature of this protein is poorly understood despite being expressed by,
and acting on, a broad range of cells. It appears to spur the induction of a wide range of
proinflammatory cytokines and receptors (reviewed by Rosado & Rodriguez-Sosa 2011).
Researchers working to construct the L. major genome noted the presence of genes
encoding a Leishmania derived MIF (LMIF) which somewhat resembles that found in
mammals (Ivens et al. 2005). It is strange that Leishmania would express this
proinflammatory protein, especially given MIF’s ability to induce NO production in
macrophages (Lan et al. 1997). Early research as to the relevance of host derived MIF
reported antiparasitic effects driven by ROS and TNF-α (Jüttner et al. 1998). Another
study using MIF deficient mice produced supportive results, showing increased
susceptibility to disease (Satoskar et al. 2001). This begs the question as to why L. major
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would express a protein that seems to contribute to its own demise. This was addressed
in a study using LMIF knockout parasites in mice. The authors noted substantially
reduced parasitemia in animals harboring knockout parasites, which were twice as
vulnerable to macrophage killing as their wild-type counterparts (Holowka et al. 2016).
These authors postulated that LMIF depletes protective T cells while others have
suggested LMIF serves the parasite by preventing apoptosis of infected macrophages
(Kamir et al. 2008). Conflicting reports between outcomes associated with host derived
MIF and LMIF highlight the need for further research into differing effector functions of
the two proteins.
In the context of leishmaniasis, the presence of M2s is associated with disease
exacerbation. It has been demonstrated that BALB/c mice lacking IL-4R exhibited
slowed disease progression and improved microbicidal activity when infected by L.
major (Holscher et al. 2006). In humans, post kala-azar dermal leishmaniasis (PKDL) is
associated with a preponderance of M2s in peripheral circulation (Mukhopadhyay et al.
2015). Expression of markers associated with the M2 profile were found to be 13-14
times higher in PKDL patients but, reassuringly, M2 markers returned to base line after
treatment with antimony or Miltefosine (Mukhopadhyay et al. 2015). Another study
noted that mice can be chemically treated to induce proliferation of M2s which
corresponded with increased severity of CL in both the BALB/c and C57BL6 models
(Vellozo et al. 2017). Experimentation with genetically attenuated strains of L. major
have shown considerable polarization to M1 phenotype compared to wild-type parasites
(Bhattacharya et al.) These findings imply parasite-mediated polarization of macrophage
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phenotype, suggesting yet another mechanism by which Leishmania is able to influence
host immunity.

Current Perspectives on Adaptive Immunity
The Th1/2 paradigm
No discussion regarding host-Leishmania interaction would be complete without
mention of the Th1/2 paradigm. By the 1970’s it was known that different inbred mouse
strains experienced markedly different outcomes with L. major infection (Nasseri &
Modabber 1979). Though the underlying mechanism behind host specific vulnerability
remained elusive. Nearly a decade later a landmark paper by Scott et al. (1988)
elucidated the issue. The authors observed that susceptible BALB/c mice could be
partially immunized against L. major using injections of SLA (soluble Leishmania
antigen). They hypothesized that the key to protective immunity against L. major was
dependent on T cell activation. In the hopes of identifying which components in
particular were responsible for protective effects, they fractionated the SLA to examine
the constituents. These fractions were assayed to measure their stimulatory effects on T
cells. Two fractions activated T cells but only one was protective. From here they were
able to identify the cytokines associated with protective and non-protective states of T
cell activation. While the Th1/2 designations had been established at the time,
substantially less was understood about their roles in disease. They observed that IL-2
and IFN-γ were associated with Th1 activation and disease healing, while IL-4 and IL-5
were associated with Th2 activation and disease progression. Other researchers would go
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on to produce supportive results, further cementing the protective role of IFN-γ and the
detrimental role of Th2 cytokines (Heinzel et al. 1989; Castellano et al. 2009; Kopf et al.
1996). The observations made by Scott and colleagues not only helped establish a
foundational understanding of immunity to Leishmania but also shaped the general
understanding of adaptive immunity.
At first glance this is a very straightforward model for understanding outcomes of
leishmaniasis. Unfortunately, the reality of the matter is not so tidy. The Th1/2
dichotomy as summarized above largely applies to only L. major infection in the BALB/c
strain. The general understanding of disease outcomes has evolved and become
incredibly nuanced. Other reviewers have noted that disease outcomes are heavily
context dependent and are influenced by species of parasite, host phenotype, mode of
infection, and organs/body site sampled (reviewed by Mears et al. 2015; Loria-Cervera &
Andrade-Navaez 2014; Loeuillet, Bañuls & Hide 2016; Alexander & Brombacher 2012).
Though the daunting minutia of study-specific results may seem confounding, there is
value in identifying overarching trends.
One such trend is the universally beneficial effects of IFN-γ (Belosevic et al.
1989; Harms et al. 1989; Robersts 2005; Castellano et al. 2009; Nylén & Gautam 2010;
Alexander & Brombacher 2012; Kumar et al. 2014; Solano-Gallego et al. 2016). The
anti-leishmanial property of IFN-γ can be attributed to its ability to induce NO production
in macrophages (Ding, Nathan & Stuehr 1988; Tötemeyer et al. 2006). IL-12 is also
considered a protective cytokine, owing to its ability to induce expression of IFN-γ
(Munder et al. 1998; Darwich et al. 2009). IFN-γ also stimulates production of IL-12,
allowing the two cytokines to form a positive feedback loop with each other (Ma et al.
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1996).
TNF-α is also widely regarded as protective against CL (Liew et al. 1990; Kemp
et al. 1999; Wilhelm et al. 2001; Tripathi, Singh & Naik 2007; Fromm et al. 2016). As
with IFN-γ, TNF-α is associated with elevated NO production in macrophages, leading to
greater parasite clearance (Lin et al. 1994; Fonseca et al. 2003). However the role of
TNF-α is somewhat more ambiguous in the context of VL. Though it has been
associated with clearance of VL (Tumang et al. 1994; Murray et al. 2000), deprivation of
TNF-α has also been shown to have no effect on parasite burden ex vivo (Singh et al.
2016). Other researchers have correlated increased splenic tissue damage in wild-type
mice when compared to TNF-α knockout mice (Engwerda et al. 2002). TNF- α has also
been associated with more severe manifestations of American leishmaniases (Castes et al.
1993; Da-Cruz et al. 1996). However these observations were made in a clinical setting
with no regard for the causative agent. Conclusions were drawn based on observed
decreases in TNF-α after treatment, which could just as well be a return to baseline
cytokine expression after recovery.
The characteristic Th2 cytokines such as IL-4, IL-5, and IL-13, are typically
considered conducive to parasite persistence but forthcoming research indicates the
reality of the matter is more complex. Though IL-4 has been associated with negative
outcomes during L. major infection (Chatelain, Varkila & Coffman 1992) it does appear
to have some role in Th1 development. Evidence would suggest that IL-4 is associated
with higher levels of IFN-γ and can induce IL-12 secretion by DCs during initial stages
of infection (Biedermann et al. 2001; Gurung & Poudel 2018). Interestingly IL-4Rα, a
receptor shared by IL-4 and IL-13, appears to have some role in resistance to L. major
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(Mohrs et al. 1999). The role of IL-4 in visceral disease is also multifaceted. Studies
using IL-4 deficient mice infected by L. donovani have produced mixed results. IL-4 has
been shown to confer either modest protection or little to no effect on parasite burden
(Stäger et al. 2003; Satoskar, Bluethmann & Alexander 1995; Alexander et al. 2000).
The latter study also hints at a potential role for IL-4 in recovery from VL. Under
treatment with antimonial drugs, mice lacking IL-4 have an impaired ability to resolve
infection compared to wild-type animals (Alexander et al. 2000). IL-13 has considerable
functional overlap with IL-4 due to the two cytokines having shared structural motifs and
receptor homologies (Zurawski et al. 1993; Mueller et al. 2002). For this reason, IL-13
very closely mimics the effects of IL-4 during Leishmania infection. As with IL-4, IL-13
is implicated in progression of CL, both Old World and New World (Coêlho et al. 2010;
Matthews et al. 2000; Bourreau et al. 2001; Alexander et al. 2002). IL-13 also appears to
impart some protection against L. donovani (Murray et al. 2006; McFarlane et al. 2011).
Publications on the roles of IL-5 are somewhat sparse. Studies have provided indirect
evidence for a potentially protective role for IL-5 in L. amazonensis and L. infantum
infection (Watanabe et al. 2004; Mary et al. 1999). However, further study is required
before serious conclusions can be drawn with regard to IL-5.
The growing body of knowledge regarding Th1/2 responses to leishmaniasis
would indicate that the old presupposition of Th1 being protective and Th2 being
detrimental is not entirely accurate. As mentioned above, Th2 cytokines can have
protective effects and may be involved in regulating Th1 development. It is the opinion
of this reviewer that it is not necessarily the presence of a Th2 response that is
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disadvantageous, but rather the absence of a Th1 response that leads to increased disease
severity.
Roles for other CD4 T cell subtypes
Since the Th1/2 CD4 cell subtypes were first described by Mosmann et al. (1986),
other subsets of T helper cells have been identified. Of particular note are Th17 and Treg
cells. Th17 cells, first described by Harrington et al. (2005), differentiate upon activation
by IL-6 and TGF-β or IL-21 (Mangan et al. 2006; Bettelli et al. 2006; Nurieva et al.
2007). Characteristic Th17 effector cytokines include IL-17, IL-21, and IL-22 (Park et
al. 2005; Korn et al. 2007; Chung et al. 2006). Th17 cells are involved in autoimmunity
and it has been theorized their evolutionary purpose is to mount fierce inflammatory
reactions against extracellular pathogens that cannot be adequately dealt with by Th1 or
Th2 cells (reviewed by Korn et al. 2009). Due to this destructive capability, the Th17
response is often associated with tissue damage and this would seem to be the case in CL.
The presence of Th17 cells and their constituent cytokines has been implicated in
increased severity of infection caused by L. major, L. mexicana, and L. guyanensis
(Kostka et al. 2009; Anderson et al. 2009; Pedraza-Zamora et al. 2017; Hartley et al.
2016). Th17 cells appear to have a generally protective effect against VL. A number of
publications have reported protective effects against L. donovani and L. infantum (Pitta et
al. 2009; Ghosh et al. 2012; Nascimento et al. 2015; Quirino et al. 2016). This could be
explained, at least in part, by increased neutrophil recruitment to affected organs. IL-17
has been linked to increased expression of CXCL1, a neutrophil chemoattractant (Liang
et al. 2007). A more recent study was able to directly link disease resistance to neutrophil
infiltration mediated by IL-17 (Quirino et al. 2016).
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Historically, IL-6 has been considered a Th2 cytokine and has been studied as
such. Though IL-6 has since been reclassified as a Th17-promoting cytokine the body of
work behind it is valuable. Observational clinical studies on VL have associated IL-6
with symptomatic leishmaniasis and more severe forms of disease (de Lima, Peiro &
Vasconcelos 2007; dos Santos et al. 2016; Ansari, Ramesh & Salotra 2006). However,
these studies are correlational and cannot show causation between IL-6 and disease
progression. Similar clinical studies on American leishmaniasis show a link between
active disease and IL-6 production, but again it is unclear if IL-6 is effectual in disease
progression (de Lima, Peiro & Vasconcelos 2007; Gomes et al. 2014; Espir et al. 2014).
This is in contrast to experimental studies which, with some exception (Murray 2008),
suggest a mildly protective role against Old World CL and VL (Titus et al. 2001; Stäger
et al. 2006; Kling et al. 2011).
Treg cells, as the name would imply, are functionally characterized by their role in
down-regulating inflammatory responses via secretion of IL-10 (Rubtsov et al. 2008;
Chaudhry et al. 2011). One might expect that reduced inflammation may be beneficial, at
least during CL infection, but this does not seem to be the case. Treg cells and IL-10 are
associated with parasite persistence in infection by L. major, L. donovani, and L.
guyanensis (Belkaid et al. 2002; Kane & Mosser 2001; Murphy et al. 2001; Singh et al.
2012; Rai et al. 2012; Bourreau et al. 2009). However, experimental depletion of Treg
cells would indicate that they do play a role in preventing pathology caused by
inflammatory damage resulting from L. panamensis infection (Ji et al. 2005). A similar
outcome was observed after using adoptive transfer of Treg cells specifically immunized
to L. amazonensis (Ji et al. 2005). Treg cells and IL-10 are also thought to be responsible
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for non-sterile cure observed in recovered subjects (Belkaid et al. 2002; Mendez et al.
2004; Falcão et al. 2014). Prevention of full parasite clearance may initially seem
undesirable, however these same studies demonstrated that the minute parasite
persistence afforded by Treg cells and IL-10 helps confer lasting immunity to future
exposures.
CD8 T cells
The role of CD8 cells in leishmaniasis could be described as “a double edged
sword”. Conventional wisdom would suggest that CD8s are beneficial, given their
cytotoxic ability, but this does not seem to be the case. Heavily cytolytic CD8s, as
measured by granzyme expression, have been correlated with more severe lesions caused
by CL in both humans and mice (Moll et al. 1991; Faria et al. 2009). This correlation
was further examined using perforin deficient mice. The absence of perforin did not
affect lesion development caused by L. major (Conceição‐Silva et al. 2006). This effect
was further examined using Rag1 knockout mice, which lack both T and B cells. After
infection with L. braziliensis, Rag1 -/- mice received transfers of wild-type or perforin
knockout CD8s. Mice that received perforin-free CD8s exhibited reduced lesion
development, suggesting a link between CD8 mediated cytolytic activity and tissue
damage caused by CL (Novais et al. 2013). It should however be noted that reduced
lesion development in Rag1 knockout mice does not correlate with decreased parasite
burden, only reduced pathology (Belkaid et al. 2002; Novais et al. 2013). Disease
progression associated with CD8 cells has also been linked to inflammasome activation
mediated by IL-1β (Novais et al. 2017)
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CD8 cells are not exclusively harmful by any measure. A number of studies have
demonstrated beneficial effects associated with the presence of CD8s in both CL and VL
(Stern et al. 1988; Müller et al. 1993; Alexander, Kaye & Engwerda 2001; Belkaid et al.
2002; Uzonna, Joyce & Scott 2004; Murray et al. 2015). The protective effect offered by
CD8 cells is tied to their ability to induce IFN-γ secretion (Müller et al. 1993; Belkaid et
al. 2002; Uzonna, Joyce & Scott 2004; Murray et al. 2015). Uzonna, Joyce & Scott
demonstrated this particularly well in their publication (2004). They first demonstrated
the adoption of a Th2 response in separate groups of knockout mice that had been
deprived of either CD8 cells or β-2 microglobulin, a component of MHCI. Infected CD8
knockout mice were then given either CD8 cells from wild-type mice or IFN-γ knockout
mice. Those that received wild-type, IFN-γ competent CD8s exhibited recovery; while
the group that received IFN-γ deficient CD8s showed lesion development and
parasitemia comparable to the CD8 knockout group. Cytotoxic T cells are also believed
to contribute to lasting immunity after immunization or recovery from leishmaniasis.
CD8s mediate immunity to secondary exposure by mounting a memory response
characterized by heavy secretion of IFN-γ (Müller et al. 1993; Rhee et al. 2002).
B cells
Current literature regarding the role of B cells in leishmaniasis suggests that these
lymphocytes are inconsequential at best. One study used mice lacking competent B cells
to investigate what outcome this may have on L. donovani infection. The knockout mice
exhibited reduced parasite burdens compared to the controls, but at the cost of somewhat
greater liver pathology (Smelt et al. 2000). This same study linked this liver damage to
neutrophil activity independent of T cells. They also observed no difference in
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antiparasitic capability of CD4 cells from B cell deficient mice and wild-type. These
results would suggest that the increased disease severity associated with presence of B
cells is unrelated to CD4 activity. Another research group has also reported negative
outcomes of L. donovani infection in presence of intact B cells. They observed B cell
activation mediated by endosomal TLRs is responsible for a weakened Th1 response and
hypergammaglobulinemia (Silva-Barrios et al. 2016). The authors go on to link B cell
TLR action with subsequent secretion of IL-10 and type-I IFN. They suggest that
stimulation by these cytokines upregulates TLR expression, creating a positive feedback
loop. Studies on American CL with regard to B cells have produced inconclusive results.
One study using L. panamensis reported smaller lesions in B cell deficient animals but
also feeble IFN-γ production compared to the control (Wanasen, Xin & Soong 2008).
Another group described an interplay between human derived CD4 cells and B cells in
the presence of L. panamensis antigen that leads to substantial upregulation of some
eleven cytokines (Rodriguez-Pinto, Saravia & McMahon-Pratt 2014). What influence
this may have on disease is not known.
Macrophage subtype
Macrophages are often associated with innate immunity but they do play a part in
shaping the adaptive response and are heavily influenced effectors of adaptive immunity.
Studies examining the effect of macrophage subtype on Leishmania infection are scarce
but the concept is worth discussing. It was first observed in 1962 that intracellular
infection by Listeria could induce lasting changes in the phenotype and microbicidial
activity in macrophages independent of serum immunity (Mackaness 1962). It was noted
that peritoneal macrophages from recovered mice were markedly more resistant to death
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and had enhanced pathogen-killing capability. More interesting still, the immune
macrophages retained their abilities even after sterile cure, though resistance began to
diminish after three weeks. The resistance did not disappear entirely, however.
Mackaness postulated that this depends “…upon an ability to generate a new population
of resistant cells from a residuum of specifically sensitized macrophages or macrophage
precursors still surviving in the tissues…” (Mackaness 1962, pg. 405).
Later, these differing macrophage profiles were tied to the Th1/2 paradigm of
acquired immunity and in 2000 the designations of M1/2 were coined (Mills et al. 2000).
It has been pointed out that the M1/2 classification has some inconsistencies and
limitations (Murray et al. 2014; Martinez & Gordon 2014). Without an improved
systematic approach to macrophage activation the M1/2 paradigm will have to do for
now. M1 macrophages are associated with type 1 inflammation, tumor resistance, and
killing of intracellular pathogens while M2s can be immune regulatory, involved with
wound healing, type 2 inflammation, and extracellular parasite killing (Mantovani et al.
2004). Generally speaking, M1 macrophages correspond to the Th1 cytokines TNF-α,
IFN-γ, and/or bacterial lipopolysaccharide. M2 macrophages on the other hand are
activated by the Th2 cytokines IL-4, IL-13, IL-1R ligands, and IL-10 (Mantovani et al.
2004). Ideally, a host’s physiology will be able to balance the competing processes
throughout the course of infection in order to clear offending pathogens while minimizing
self-harm.
Summary
The genus Leishmania was initially discovered and identified at the turn of the
20th century by British medical officers working in India. Much earlier references to
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leishmaniasis exist, but it was the work of William B. Leishman, Charles Donovan, and
Ronald Ross that was able to link kala-azar to this particular parasite. They were also the
first to determine that the parasites were trypanomastids. Later, Max Luhe was able to
classify the causative agents of both CL and VL as being Leishmania. The parasites
where then discovered in the Americas and described by Antonio Carini, Ulysses de
Freitas Paranhos, and Adolpho Lindenberg. American Leishmania was determined to be
distinct from Old World Leishmania by Edmundo Escomel and Gaspar Vianna.
The genus Leishmania is subdivided into multiple subgenera. The two that are
relevant to human health are subgenera Leishmania and Viannia. The subgenous Viannia
exists exclusively in the New World while subgenous Leishmania is represented in both
the Old World and New World. This raises questions as to the geographic origin of the
parasite and how it came to be distributed across the globe. A number of theories have
been put forth but the hypothesis that carries the most support at this time suggests that
the ancestors of modern Leishmania evolved on the supercontinent of Gondwana.
Subgernera Leishmania and Viannia were isolated from one another as the Atlantic
Ocean widened. It is believed that subgenous Leishmania was introduced to the New
World via the Baring land bridge during the Eocene. This introduction is hypothesized to
have given rise to members of the L. mexicana species complex. It also believed that L.
infantum was introduced to the New World very recently, during colonization by
Europeans.
Leishmaniasis is a highly nuanced disease, the outcome of which depends on
multiple factors including parasite species, host immunophenotype, and host immune
status. The interplay between host immunity and parasite virulence factors is complex
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and our understanding of it is continually being refined. During initial exposure,
Leishmania uses a variety of methods to establish infection and survive innate immunity.
The process begins within the sandfly vector, wherein the parasite alters host physiology
to encourage more tenacious feeding and increase chances of successful transmission.
The parasite then works to survive an innate response by preferentially allowing
opsonization by iC3b, prevention of MAC formation, and neutrophil manipulation.
Leishmania must then gain silent entry to macrophages through selective activation of
particular compliment receptors, TLRs, MFR, and apoptotic mimicry. It avoids
destruction in the phagosome by preventing fusion with the lysosome, impeding
production of ROS and NO, and scavenging resources for survival.
Infection is maintained by subversion of the adaptive immune response. CD4 T
cell activation is critical for parasite clearance. A Th1 response, dominated by IFN-γ
production is beneficial and conducive of cure. The Th2 response, historically thought to
be detrimental, can actually confer protective effects under certain circumstances. It is a
lack of Th1 activity that leads to injurious effects, rather than the presence of Th2
activity. Contemporary understanding of leishmaniasis includes roles for other CD4 T
cells, particularly Th17 and Treg. Th17 cells are associated with tissue damage during
CL, likely owing to their powerful inflammatory abilities. On the other hand, Th17 cells
seem to protect against dissemination of VL. Treg cells are associated with parasite
persistence but also play a role in limiting inflammatory tissue damage. Treg cells are also
partially responsible for preventing sterile cure, which allows for lasting immunity to
future exposures. CD8 T cells cause tissue damage resulting from their cytolytic
activities but also aid in recovery by spurring IFN-γ production. B cells seem to play a
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minimal role in leishmaniasis, and can be considered to have mildly negative to neutral
effects on disease progression.
Despite having been discovered and identified well over a century ago,
Leishmania still perplexes modern researchers. From its ambiguous evolutionary origins
and world-wide dispersal, to its complex interactions with host immunity, there is still
much to learn about this unique and prolific parasite.
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CHAPTER III
METHODS
Animals
BALB/c mice were originally procured from Simonsen Laboratories (Gilroy, CA)
and propagated in the CWU vivarium. They were housed under controlled light and
temperature conditions with food and water provided ad libitum. All procedures were
carried out in compliance with IACUC approved protocols #A01170.
Cells
J774 murine macrophage line (ATCC TIB-67™) was cultured in high glucose
DMEM with sodium pyruvate (GE Healthcare Bio-Sciences, USA) fortified with 6mM
L-glutamine and 10% heat-inactivated FCS (Gemini, Sacremento, CA). Cells were
incubated at 37oC in a humidified atmosphere with 5% CO2.
Leishmania parasites were cultured in Schneider’s complete insect medium
(Sigma-Aldrich, USA) with 15% heat-inactivated FCS and incubated at 24oC. Prior to
culture, parasites were kept in liquid nitrogen and virulence was maintained by passage
through BALB/c mice. Both L. major, strain MHOM/IL/79/LRC-L251 and L. infantum,
MHOM/ES/92/LLM-320 were originally provided by Dr. Diane McMahon-Pratt (Yale
School of Medicine, New Haven, CT).
ELISA
Soluble Leishmania antigen (SLA) was prepared by washing parasites and
resuspending in PBS. The suspension was then frozen overnight at -18oC to lyse cells.
The solution was thawed and homogenized using sonication (Misonix, Farmingdale, NY)
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at setting 12 for 3-15 second intervals. SLA was adjusted to a concentration of 1mg/ml
and 100µl per well was added to a 96-well plate. The antigen was allowed to set
overnight at 4oC. The plate was then washed five times with PBS+.05% Tween20 (PBST). Blocking buffer was made using PBS-T+1% milk and 200ul was added to each well
and allowed to set for two hours on the benchtop. The plate was again washed and 100ul
serum solution was added to each well and allowed to set overnight at 4oC. Serum from
three control animals and three infected animals was diluted 1:50 and 1:100 in blocking
buffer and each dilution was measured in duplicate. The plate was then washed and
100µl secondary antibody solution was added to each well. Goat anti-mouse IgG
conjugated with horse radish peroxidase (HRP) was used as secondary antibody and
diluted 1:3000 in blocking buffer, according to manufacturer’s instructions (Bio-rad,
Hercules, CA). After a two hour incubation at room temperature, plates were washed
again and 100µl HRP substrate solution (Thermo-Fisher, Rockfield, IL) was added to
each well. Absorbance at 405nm was then measured every five minutes for 30 minutes
using a BioTek plate reader (Winooski, VT). A two-tailed Student’s T test assuming
unequal variances was used to compare serum affinity for L. major and L. infantum SLA.
Fluorescent microscopy
To demonstrate progressive infection of cells, fluorescent staining was used for
photomicroscopy. Cells were harvested, enumerated, reacted, fixed, and stained as
described for flow cytometry. In addition to PI being used to stain nuclei and
kinetoplasts, membranes were counter stained using fluorescein isothiocyanate (FITC)conjugated wheat germ agglutinin (WGA), 1µg/ml (Vector Labs, Burlingame, CA).
Stains were allowed to set for 30 minutes in darkness and at room temperature. Photos
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were taken using a Leica DMRB microscope with Leica application suite software.
(Wetzlar, Germany).
Phagocytosis assays
Prior to in vitro experimentation, serum used to treat cells was produced and
harvested as follows: L. major was cultured until determined by visual inspection that
metacyclic promastigotes predominated the medium. Parasites were removed from the
medium via centrifugation at 1000 rpm for ten minutes. Metacyclic promastigotes were
then isolated using a Percoll (Sigma-Aldrich, St. Louis, MO) density gradient as
previously described (Ahmed et al. 2003).

Promastigotes were then suspended in sterile

PBS to a concentration of 106 cells/ml. A 10µl dose, delivering 104 promastigotes was
injected into the left rear paw of BALB/c mice. The infection was allowed to progress
for twelve months prior to serum collection. Control serum was collected from age/sex
matched animals.
J774s and Leishmania were harvested and enumerated using a hemocytometer.
Treatments of either no serum, naïve serum, or L. major antiserum were administered to
Leishmania using 1µl serum to 1ml cell culture. Serum was added directly to culture
medium and allowed to incubate for 30 minutes. Concentration of J774s was adjusted to
1.25 x 105 and reacted with Leishmania at a 1:10 ratio in cDMEM. Reacting cells were
incubated at 37oC in a humidified atmosphere with 5% CO2. Samples were collected in
triplicate at 0, 12, 18, and 24 hours. Once collected, samples were incrementally fixed to
minimize clumping, first with 35% EtOH and then in 70% EtOH.
Prior to analysis, samples were resuspended in PBS and adjusted to a
concentration of 5 x 105 cells per milliliter. Cells were stained using propidium iodide
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(PI), 1µg/ml. Flow cytometry was carried out using an S3 cell sorter (Bio-Rad, Hercules,
CA). A multiparametric protocol was devised to quantify unbound parasites via forward
scatter, side scatter, and PI fluorescence. Data on 3 X 104 events were collected from
each sample. Data were then analyzed using FlowJo software (FlowJo, Ashland, OR).
Statistical significance was determined using Graphpad Prism software (La Jolla, CA) to
carry out an ANOVA test coupled with Tukey’s comparison.
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CHAPTER IV
RESULTS
Serum cross reactivity
To verify the cross reactivity of L. major antibody against L. infantum antigen an
ELISA was performed (Figure 9). Wells were coated with both L. infantum SLA as well
as L. major SLA to serve as positive control. Results indicate substantial cross reactivity
between the two parasites.
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Figure 9: ELISA results measuring affinity of L. major antiserum for L. major and L. infantum
soluble Leishmania antigen. Each bar represents serum derived from one individual. Sera were
measured in duplicate and bars connote the average of measurements. Serum dilutions of 1:50 and
1:100 were used. NS= no serum control, CS= control serum, Lm= L. major, Li= L. infantum

Phagocytosis assays
In vitro experiments were performed to determine whether L. major antiserum
will increase rates of parasite uptake by host macrophages. J774 monocytes were
combined with L. major in the presence of L. major antiserum, naïve serum, or no serum.
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Samples were collected at 0, 12, 18, and 24 hours after combining host cells and
parasites. Progression of infection was verified using fluorescent microscopy (Figure
10). Data were gathered in histogram format and free parasites were quantified (Figure
11). As expected, parasite uptake in the presence of immunized serum was significantly
higher than with control serum or no serum (Figure 12, 14A).
Having established proof of principle, the same experiment was carried out using
L. infantum. Under these same conditions, no increased parasite uptake was observed in
the presence of L. major antiserum (Figure 13, 14B).

A

B

C

D

Figure 10: Progression of L. major infection of J774s. Photos depict- A: uninfected cell,
B: recently infected cell, C: heavily infected cells, D: Heavily infected cells nearing death.
Nuclei and kinetoplasts were stained red with propidium iodide. Membranes stained green
with FITC- conjugated wheat germ agglutinin.
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LmS

NS

Figure 11: Sample of raw data used to construct graphs shown in figures 12 & 13. Histogram
data showing peaks that correspond to free parasites and host macrophages. Gates denote the
percentage of events within the selected range and correspond to free parasites and infected
macrophages. Both panels depict measurements taken at 24 hours after cells were combined. NS=
no serum, LmS= L. major antiserum.
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Figure 12. Free L. major in the presence of L. major antiserum, control serum, and no serum.
Lines represent uninternalized L. major with standard error. NS= no serum, CS= control serum,
LmS= L. major antiserum.
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Figure 13. Free L. infantum in the presence of L. major antiserum, control serum, and no
serum. Lines represent uninternalized L. infantum with standard error. NS= no serum, CS=
control serum, LmS= L. major antiserum.
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Figure 14. Infected macrophages at 24 hours. Bars represent averaged percentage of events
corresponding to infected macrophages at 24 hours with standard error. A: cells infected by L. major,
B: cells infected by L. infantum. Panels A & B correspond with figures 12 & 13, respectively. NS=
no serum, CS= control serum, LmS= L. major antiserum.
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CHAPTER V
DISCUSSION
Using ELISA, we demonstrated substantial cross reactivity of L. major antiserum
against L. infantum SLA (Figure 9). This was to be expected as previous works have
demonstrated not only significant cross reactivity between Leishmania species, but even
between other genera of Trypanosoma (Malchiodi et al. 1994; Vexenat, Santana &
Teixeira 1996; Vale et al. 2009). This result establishes a basic premise of this study; the
presence of cross reactive antibody is requisite if ADE is occurring in this model. We
then moved onto the phagocytosis assays. These were designed to determine if L. major
antiserum induces increased uptake of L. infantum in vitro. Allowing parasites, host
cells, and serum interact in vitro enables us to attribute any increased parasite uptake to
extrinsic ADE. Extrinsic ADE is generally defined increasing rates of infection purely
through the effect of opsonization, allowing a pathogen to bind or come in close
proximity to leukocytes, leading to higher rates of pathogen internalization. Intrinsic
ADE is characterized by host cells becoming more receptive and less hostile toward
potential attackers. It is caused by changes in cell signaling, especially increased IL-10
produced as a result of Fcγ-FcγR signaling (Anderson, Gerber & Mosser 2002).
To address the possibility of extrinsic ADE we proceeded to carry out
phagocytosis assays to measure uptake of parasites by J774 macrophages in the presence
of either naïve serum, L. major antiserum, or no serum. The amount of
unbound/uninternalized parasites was measured using flow cytometry. To validate the
technique, uptake of L. major in the presence of L. major antiserum was first observed
(Figure 12). We noted significantly lower numbers of free parasites treated with
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antiserum compared to those treated with naïve serum or no serum, as expected. We also
observed significantly higher rates of L. major infection among host cells in the presence
of L. major antiserum (Figure 14A). This process was repeated to measure changing
amounts of free L. infantum under the same conditions. Interestingly, L. major antiserum
had no effect on L. infantum uptake or numbers of infected host cells (Figure 13&14B).
This result would suggest that the heterologous disease exacerbation observed in vivo
(Nation, Dondji & Stryker 2012; Anderson, Dondji & Styker 2014) cannot be attributed
to extrinsic ADE.
This potentially leaves two explanations as to why increased parasite burden was
observed by others in vivo. The first would of course be intrinsic ADE. In short, the
circulating antibody opsonized the parasites, attracting macrophages which bound the
antibody, inducing IL-10 production through Fcγ signaling (Anderson, Gerber & Mosser
2002). The IL-10 in turn down regulated the microbicidal response of macrophages
allowing for easier entry and more hospitable conditions for L. infantum (Kane & Mosser
2001). The reason this effect was not observed in vitro could be attributed to a lack of
other leukocytes to reinforce effector cytokine functions.
The supposition that intrinsic ADE is at play fails to address the findings of
Romano et al. (2015) who observed protective effects against L. infantum after
immunization with live L. major. These authors opted to use the C57BL6 model, known
for its predisposition for the Th1 adaptive response and relative resistance to Old World
CL (Scott 1988 & 1989; Heinzel et al. 1991). Knowing this, it may come as no surprise
that C57BL6s are able to quell leishmaniasis, given their propensity toward the typically
protective cytokines IFN-γ and TNFα (Heinzel et al. 1989; Wilhelm et al. 2001).
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However, in consideration of our current results and the observations of others, we
hypothesize that biased memory T cell responses can account for these seemingly
conflicting observations. It has been shown that macrophages are capable of activating
CD4 cells and influencing whether they will be directed toward the Th1 or Th2
phenotype (Anderson & Mosser 2002). Macrophages from resistant and vulnerable
mouse strains tend to have correspondingly biased phenotypes (Buchmüller-Rouiller &
Mauël 1986). These biased macrophages are classified as M1 and M2 and have cytokine
profiles analogous to those of Th1 and Th2 CD4 cells respectively (Mills et al. 2000).
Anderson & Mosser (2002) eloquently demonstrated that CD4 cells will retain the bias of
the macrophages which originally activated them. Furthermore, CD4s will react to
repeated exposures to presented antigen in the same manner they did during first
exposure, even in the absence of biasing conditions, and even when activated by different
types of APC (Anderson & Mosser 2002). In light of this information, we postulate that
the heavily biased adaptive responses of the BALB/c and C57BL6 models will give rise
to correspondingly biased T cell populations after first exposure to L. major. These T
cells will then retain their biases, whether protective or detrimental, and react in the same
manner upon subsequent exposure to similar antigens. In short, the systems are biased to
begin with and these biases are only reinforced with subsequent exposures. Additional
experimentation examining T cell polarization as a result of activation by macrophages
within these biased models is necessary to further elucidate this issue.
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